Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
The Pharmacist’s Guide to Patient Identification, Testing, and Antiviral Use.
Choose from the criteria below to find an activity that fits you best.
Although there are several effective treatment options for newly diagnosed Multiple
Myeloma (MM), most patients will experience relapse and eventually become refractory
to multiple lines of therapy. In recent years, the treatment of MM has changed dramatically
because of the approval and subsequent expanded indications of several new agents.
As experts in medication therapy management, pharmacists are uniquely positioned to manage adverse events associated with relapsed/refractory MM therapies. Education on the treatment options for relapsed/refractory multiple myeloma (R/R MM) and how to design optimal therapeutic regimens, including monitoring parameters and appropriate patient counseling, will improve patient outcomes and quality of life.
During this activity, faculty will discuss case scenarios highlighting current challenges with therapy selection, sequencing, and treatment planning for patients with R/R MM; discuss areas of consensus; debate areas of controversy; and elucidate how the latest data fit into the treatment algorithm going forward.
The target audience for this activity includes pharmacists, including clinical and health-system pharmacists, board-certified oncology pharmacists, specialty pharmacy and managed care professionals, and other pharmacists responsible for the care and management of patients with relapsed/refractory multiple myeloma. At the completion of this activity, the participant will be able to:
Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma
Winship Cancer Institute, Emory Healthcare
Tim Peterson, PharmD, BCOP
Clinical Pharmacy Specialist – Multiple Myeloma
Memorial Sloan Kettering Cancer Center
New York, New York
Release Date: August 2, 2021
Expiration Date: September 20, 2022
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-21-168-H01-P
has been assigned to this home-study, knowledge-based activity. This activity is approved
for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. The activity
is provided at no cost to participants. Completion of an evaluation and post-test
with a score of 70% or higher is required to receive CE credit. No partial credit
will be given. Statements of completion will be issued online at www.ProCE.com, and
proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Maples has received consulting fees from GlaxoSmithKline, Janssen, Karyopharm, and Sanofi. Dr. Peterson has received consulting fees from GlaxoSmithKline.
This activity is supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.